INTRODUCTION: We sought to determine whether 18- to 22-mo neurodevelopmental outcomes predicted functional outcomes at 7-8 y for survivors of the CoolCap study of therapeutic hypothermia for neonates with hypoxic-ischemic encephalopathy. RESULTS:WeeFIM ratings were completed at 7-8 y of age on 62 (32 cooled; 30 standard care) of 135 surviving children who had had neurodevelopmental assessment at 18 mo. There was 1 refusal, 58 lost to follow-up, and 14 children whose centers declined to participate. Disability status at 18 mo was strongly associated with WeeFIM ratings (P < 0.001); there was no significant effect of treatment (P = 0.83). DISCUSSION: Functional outcome at 7-8 y of survivors of neonatal encephalopathy is associated with 18-mo neurodevelopmental assessment, supporting the long-term predictive value of a favorable outcome at 18 mo assessed by published trials of therapeutic hypothermia. METHODS:All surviving children who participated in the CoolCap study and were assessed at 18 mo were eligible for reassessment using the WeeFIM instrument that qualitatively measures self-care, mobility, and cognitive function. Center investigators obtained consent from the families for a certified researcher to administer the WeeFIM instrument by phone.
RCT Entities:
INTRODUCTION: We sought to determine whether 18- to 22-mo neurodevelopmental outcomes predicted functional outcomes at 7-8 y for survivors of the CoolCap study of therapeutic hypothermia for neonates with hypoxic-ischemicencephalopathy. RESULTS: WeeFIM ratings were completed at 7-8 y of age on 62 (32 cooled; 30 standard care) of 135 surviving children who had had neurodevelopmental assessment at 18 mo. There was 1 refusal, 58 lost to follow-up, and 14 children whose centers declined to participate. Disability status at 18 mo was strongly associated with WeeFIM ratings (P < 0.001); there was no significant effect of treatment (P = 0.83). DISCUSSION: Functional outcome at 7-8 y of survivors of neonatal encephalopathy is associated with 18-mo neurodevelopmental assessment, supporting the long-term predictive value of a favorable outcome at 18 mo assessed by published trials of therapeutic hypothermia. METHODS: All surviving children who participated in the CoolCap study and were assessed at 18 mo were eligible for reassessment using the WeeFIM instrument that qualitatively measures self-care, mobility, and cognitive function. Center investigators obtained consent from the families for a certified researcher to administer the WeeFIM instrument by phone.
Authors: Renée A Shellhaas; Juhi S Kushwaha; Melissa A Plegue; David T Selewski; John D E Barks Journal: J Child Neurol Date: 2015-02-27 Impact factor: 1.987
Authors: Joanne O Davidson; Alexandra L Rout; Guido Wassink; Caroline A Yuill; Frank G Zhang; Colin R Green; Laura Bennet; Alistair J Gunn Journal: J Cereb Blood Flow Metab Date: 2015-07-15 Impact factor: 6.200
Authors: Chrysanthy Ikonomidou; George Kirvassilis; Brant S Swiney; Sophie H Wang; Jacob N Huffman; Sasha L Williams; Kobe Masuoka; Saverio Capuano; Kevin R Brunner; Kristin Crosno; Heather S Simmons; Andres F Mejia; Christopher A Turski; Ansgar Brambrink; Kevin K Noguchi Journal: Neurobiol Dis Date: 2019-06-05 Impact factor: 5.996
Authors: Betty R Vohr; Bonnie E Stephens; Scott A McDonald; Richard A Ehrenkranz; Abbot R Laptook; Athina Pappas; Susan R Hintz; Seetha Shankaran; Rosemary D Higgins; Abhik Das Journal: Pediatrics Date: 2013-09-09 Impact factor: 7.124
Authors: Susan E Jacobs; Marie Berg; Rod Hunt; William O Tarnow-Mordi; Terrie E Inder; Peter G Davis Journal: Cochrane Database Syst Rev Date: 2013-01-31